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Abstract 
Acute mountain sickness (AMS) is a common problem among visitors at high altitude, 
and may progress to life-threatening pulmonary and cerebral oedema in a minority of 
cases. International consensus defines AMS as a constellation of subjective, non-specific 
symptoms. Specifically, headache, sleep disturbance, fatigue and dizziness are given 
equal diagnostic weighting. Different pathophysiological mechanisms are now thought 
to underlie headache and sleep disturbance during acute exposure to high altitude. 
Hence, these symptoms may not belong together as a single syndrome. Using a novel 
visual analogue scale (VAS), we sought to undertake a systematic exploration of the 
symptomatology of AMS using an unbiased, data-driven approach originally designed 
for analysis of gene expression. Symptom scores were collected from 293 subjects 
during 1110 subject-days at altitudes between 3650m and 5200m on Apex expeditions 
to Bolivia and Kilimanjaro. Three distinct patterns of symptoms were consistently 
identified. Although fatigue is a ubiquitous finding, sleep disturbance and headache are 
each commonly reported without the other. The commonest pattern of symptoms was 
sleep disturbance and fatigue, with little or no headache.  In subjects reporting severe 
headache, 40% did not report sleep disturbance. Sleep disturbance correlates poorly 
with other symptoms of AMS (Pearson r = 0.31 vs headache). These results challenge 
the accepted paradigm that AMS is a single disease process and describe at least two 
distinct syndromes following acute ascent to high altitude. This approach to analysing 
symptom patterns has potential utility in other clinical syndromes. 
Key Words: Acute mountain sickness, sleep, headache, visual analogue scale, BioLayout 
Express 3D 
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Introduction 
Acute mountain sickness (AMS) occurs in up to 50% of individuals ascending to high 
altitude (Maggiorini et al., 1990) and may progress to life-threatening pulmonary and 
cerebral oedema in a minority of cases (Roach, and  Hackett, 2001).  The present 
international consensus defines AMS as a collection of subjective, non-specific 
symptoms(Roach et al., 1993). Specifically, headache, sleep disturbance, and vague 
symptoms of fatigue and dizziness and given equal diagnostic weighting. Since we lack a 
common underlying mechanism to explain these symptoms, it is far from certain that 
they belong together as a single syndrome. 
 
The most frequently-used criteria for the definition of AMS are based on the self-
reported Lake Louise consensus scoring system (LLS) (Roach et al., 1993). A positive 
Lake Louise Score can describe a spectrum of non-specific symptoms experienced on 
exposure to high altitude, and these may encompass more than one disease phenotype 
(West, 2011).   
 
Headache is the cardinal feature of the LLS and is required under the present criteria for 
diagnosis of AMS (Roach et al., 1993). There is evidence to suggest that the development 
of mild vasogenic cerebral oedema leading to increased intracranial pressure may be an 
important factor in the development of high altitude headache and AMS (Kallenberg et 
al., 2007). Optic nerve sheath diameter, an indirect measure of intracranial pressure, 
increases with altitude and also correlates with AMS score (Fagenholz et al., 2009; 
Sutherland et al., 2008). Several small case series in which participants were subjected 
to simulated high altitude before undergoing cerebral MRI also demonstrated an 
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increase in brain volume (Kallenberg et al., 2007; Morocz et al., 2001). A related 
hypothesis proposes that fluid redistribution to the intracellular space leading to 
astrocytic swelling underlies the development of symptomatic AMS (Bailey et al., 2009).  
 
In contrast, sleep disturbance at high altitude may be a mechanistically separate 
problem. Changes in the control of ventilation following acute ascent to altitude lead to 
a cyclical respiratory pattern. The hypoxic ventilatory drive causes hypocapnia and a 
reduction in respiratory drive (Wilson et al., 2009). During sleep, in the absence of the 
wakefulness drive to breathing, hypoventilation results in cyclical hypoxia and 
recurrent interruption of deep sleep stages (Burgess et al., 2004).  
 
As a categorical score, LLS is inherently disadvantaged in any attempt to quantify a 
continuous spectrum of disease severity. A further problem in the measurement of AMS 
is that LLS scores at high altitude produce a strongly skewed dataset, reducing the 
power of statistical analyses and making it difficult to quantitatively compare different 
symptoms, or to infer relationships between severity and other physiological or 
biochemical measurements.  
 
Visual analogue scales (VAS) have been rigorously validated as tools to quantify the 
severity of subjective symptoms, particularly in pain medicine (DeLoach et al., 1998; 
Gallagher et al., 2001; Price et al., 1983; Todd et al., 1996), and are increasingly accepted 
for symptom scoring at altitude (Roach, and  Kayser, 2007).  Harris et al. used VAS 
scores as an endpoint in a randomised controlled trial comparing treatments of high 
altitude headache (Harris et al., 2003). Since then, there have been four studies 
exploring the relationship between VAS and LLS describing altitude symptomatology 
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(Hext et al., 2011; Kayser et al., 2010; Van Roo et al., 2011; Wagner et al., 2007), 
consistently demonstrating a correlation between LLS and VAS, both for individual 
components of LLS and overall LLS score. However, both the linearity of the 
relationship and the threshold VAS measurement for diagnosis of AMS are poorly 
defined. Unlike LLS, which is a standardised score and comparable across different 
studies, VAS studies have used different scores and as yet there is no consensus VAS for 
altitude illness. 
 
We sought to perform an unbiased quantitative assessment of the symptomatology of 
AMS in healthy lowlanders acutely exposed to high altitude. We used a novel VAS 
questionnaire to record subjective symptoms experienced by research subjects over the 
course of 1110 subject-days at high altitude. Here we report the comparison between 
VAS and LLS, and apply a hypothesis-free clustering methodology widely used in 
transcriptomics (Hume et al., 2010) to identify different patterns of symptoms in 
individuals acutely exposed to high altitude. 
 
Materials and Methods 
Study Population 
Data were collected from subjects at high altitude during two research expeditions. 103 
participants were recruited from the Apex 2 expedition to the Bolivian Andes (Baillie et 
al., 2009; Bates et al., 2011; Thompson et al., 2006). Subjects flew to La Paz, Bolivia 
(3650 m) and after 4–5 days’ acclimatisation ascended over a period of 90 minutes to 
5200 m by off-road vehicle. 41 subjects were randomised to receive antioxidant 
supplements (1 g L-ascorbic acid, 400 IU alpha-tocopherol acetate, and 600 mg alpha-
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lipoic acid/day in four divided doses starting five days before ascent to 5200 m), 20 
subjects were randomised to receive sildenafil (150 mg daily in three divided doses) 
and the remaining 42 received placebo only. This study was approved by the Lothian 
Research Ethics Committee. Data were also included from 189 trekkers ascending to the 
Kibo Hut at 4730 m on Mt Kilimanjaro in Tanzania.  This study received ethical approval 
from the Tanzanian Institute for Medical Research and is described elsewhere (Jackson 
et al., 2010). Of 189 subjects, 149 were attempting to summit via the standard Marangu 
route, which involves sleeping at huts located at 2743 m, 3760 m and 4730 m on the 
5895 m summit attempt. Of these, 82 climbers had taken an additional rest day at 3760 
m. The remaining 40 subjects were completing the Rongai route with no fixed sleeping 
points.  
Measurement of symptoms 
Subjects were asked to complete a novel seven-question visual analogue scale (VAS) 
questionnaire during acute exposure to high altitude (conceived and designed by DJC, 
and provided in the Supplementary figure S1). This assesses five symptoms associated 
with high altitude: headache (“no headache at all” to “worst headache ever”), nausea (1. 
“I really want to be sick” to “don’t feel sick at all”; 2.“my guts are really bad” to “my guts 
are fine”), fatigue (1. “I’m totally exhausted” to “I’m full of energy”; 2. “I’m at my best” to 
“I’m at my worst”), dizziness (“no dizziness at all” to “more dizzy than ever”) and sleep 
quality (“worst night’s sleep ever” to “best night’s sleep ever”). Subjects were asked to 
score their symptoms on a spectrum between the two extreme statements by marking 
their position on a horizontal 100 mm line. On all questionnaires, the direction of the 
scales was reversed for several questions to ensure subjects paid close attention to the 
questions. Reversed VAS scales were corrected prior to analysis, such that 0mm 
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corresponded to minimal severity and 100 mm to maximal severity for all seven 
questions. Summing the seven components produced a maximum total VAS score of 700 
mm. The VAS included a quality control question, which asked with different wording 
about symptoms of fatigue in order to detect inattentive subjects. A minimum 
agreement of 40 mm was required between the responses to two questions (“I’m totally 
exhausted” to “I’m full of energy”, and “I’m at my best” to “I’m at my worst”). 
 
Subjects also completed the Lake Louise Score (LLS) questionnaire, which includes 
assessment of headache, nausea and vomiting, fatigue/weakness, dizziness and sleep 
quality. Participants score the severity of each symptom from 0 (no symptom) to three 
(maximal severity); a total score of greater than or equal to three with the presence of 
headache equates to acute mountain sickness (Roach et al., 1993).   
 
Sequential LLS and VAS data were collected daily from each of the 103 Apex 2 subjects 
over 13 days of exposure to high altitude (5 days at 3600 m, 8 days at 5200 m).  Cross-
sectional data from the 189 Kilimanjaro subjects were recorded at 4730 m during their 
ascent.  
Data Analysis 
VAS scores were measured by hand in mm. Groups of VAS questionnaires exhibiting 
similar symptom profiles were identified using a network analysis tool, BioLayout 
Express 3D, http://www.biolayout.org/ (Theocharidis et al., 2009).  This software is 
primarily used to visualize and cluster networks from microarray expression data 
(Freeman et al., 2007). We created an undirected network, in which each node 
(depicted by coloured spheres) represented one VAS questionnaire. Weighted edges 
Hall et al. Network analysis reveals distinct clinical syndromes in AMS. 
Page 9 of 30 
(interconnecting lines) between these nodes represent Pearson correlation coefficients 
(r) between the symptoms in each questionnaire above a threshold of r=0.95. The MCL 
clustering algorithm (inflation = 1.4) was used to subdivide the network into discrete 
clusters of VAS questionnaires sharing similar features (van Dongen, 2000).  
 
The relationship between symptoms was explored by generating a correlation matrix in 
Microsoft Excel between VAS scores for each of five symptoms, and in Biolayout Express 
3D. The correlation between VAS and LLS was explored using Spearman’s rank co-
efficient, calculated in R 2.13.1 (R Foundation for Statistical Computing, Vienna, 2011).  
 
A simple graphical interface was developed (Excel 2003, Microsoft Corp, Redmond, 
WA), to allow exploration of the effects of changing the weighting given to each 
symptom recorded on the VAS score, the degree of concordance required between the 
to quality control questions and the effects of square-root normalization on the LLS and 
VAS data. The full dataset and formulae for data manipulation are provided as 
supplementary information at www.altitude.org/ams.php 
 
 
Results 
Visual analogue scale (VAS) and Lake Louise Score (LLS) data were collected from 292 
individuals over the course of 1110 subject-days at high altitude. This included 189 
questionnaires from 189 subjects at the Kibo Hut (4730 m) on Mt Kilimanjaro and 921 
serial questionnaires from 103 subjects on the Apex 2 expedition. 65 questionnaires (13 
from Kilimanjaro, 52 from Apex 2, 5.9% of total questionnaires) were excluded as they 
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did not meet the minimum agreement threshold of 40 mm between the two quality 
control questions on the VAS questionnaire. This left a total of 1045 subject-days at 
altitude (176 at Kilimanjaro, 869 on Apex 2), with both corresponding VAS and LLS 
data.  
Cluster Analysis of AMS Symptoms 
In order to maximise the power to detect different patterns of associated symptoms, we 
chose a composite analysis, including all questionnaires from within 1 week of a recent 
increase in altitude. This combined data from disparate sources, with differences in 
mode and rate of ascent, geographical location and drug treatment, and includes several 
questionnaires from the same volunteers at different times. The patterns reported here 
are consistently replicated in subsets of volunteers with same location and ascent rate 
(Supplementary figure S4), from the placebo group only and including only one 
questionnaire for each volunteer (Supplementary figure S3). 
  
In order to explore different patterns of related symptoms, VAS data for the 1045 
subjects-days at altitude were analysed in BioLayout Express 3D. The network 
generated was clustered using the MCL clustering algorithm (inflation value 1.4, 
minimum cluster size 30 nodes) producing three main clusters (Figure 3). The largest 
cluster contained 407 questionnaires, and corresponded to subjects who slept poorly, 
were fatigued, but had minimal headache or other symptoms. The second cluster of 127 
questionnaires, contained subjects who reported, poor sleep, headache, and fatigue.  
The third cluster contained 43 questionnaires and corresponded to subjects who had 
little sleep disturbance, but had headache and fatigue. The remaining questionnaires did 
not form a cluster large enough to be included in the analysis – the full dataset may be 
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explored at www.altitude.org/ams.php. No relationship was seen between age or sex 
and any pattern of symptoms (Figure 4). 
Symptom Correlation 
The relationship between different symptoms (rather than symptom profiles) was also 
investigated using the correlation between two symptoms across the whole population 
of responses. Symptoms as recorded by the visual analogue scale inter-correlated as 
shown in Table 1. Sleep was most weakly correlated with the five other symptoms 
(mean correlation co-efficient 0.33), whereas fatigue was most strongly correlated with 
the other reported symptoms (mean correlation co-efficient 0.55). A network showing 
the relationship between symptoms is shown in Figure 5. 
Timing of sleep assessment 
For practical reasons, AMS questionnaires inquire about sleep quality on the night 
preceding the questionnaire. This is one reason why AMS scores are lower on the first 
day following acute ascent. However in physiological terms it is equally logical to assess 
sleep on the following night. This is particularly important when assessing the 
correlation of sleep with other symptoms, because the better sleep quality experienced 
on the night before ascent will cause an artefactual dissociation between sleep quality 
and the other symptoms of AMS.  
 
Our dataset enables us to address the effect of this change. We repeated the correlation 
analyses on a subset of questionnaires in which we substituted the sleep score from the 
following day. For both the clustering of questionnaires with similar patterns of 
symptoms (Supplementary figure S3), and the correlation between the 5 symptoms 
across all volunteers, the patterns described above were consistently replicated.  
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Quantification of severity 
384 of the 1045 questionnaires were consistent with a diagnosis of acute mountain 
sickness using the Lake Louise Score (LLS > 2 with LLS headache > 0). One subject 
developed high altitude pulmonary edema (HAPE) at 3600m; there were no cases of 
HACE (high altitude cerebral edema). The median of all LLS scores was 2 (interquartile 
range 1-4). The mean total VAS was 192.6 mm with a standard deviation of 124.3 mm.  
A square-root transformation resulted in normalisation of the VAS data (Kolmogorov-
Smirnov test: KS distance 0.02036, P>0.10) but not the LLS data (Kolmogorov-Smirnov 
test: KS distance 0.1620, P<0.0001) (Figure 2).  
 
Discussion and Conclusion 
The scale of the dataset collated here, collected during 1110 subject-days at altitude, 
enables for the first time a comprehensive quantitative analysis of symptom correlation 
in altitude illness. We show that sleep disturbance is an outlier, correlating poorly with 
other symptoms of AMS. By identifying clusters sharing common patterns of symptoms, 
we demonstrate that distinct patterns of disease are primarily characterised by the 
presence of sleep disturbance or headache.  
 
Among symptomatic individuals following acute ascent to high altitude, some degree of 
fatigue was a ubiquitous finding.  In contrast, sleep disturbance and headache are each 
commonly reported without the other. This is consistent with the hypothesis that 
distinct pathogenetic mechanisms underlie sleep disturbance and headache at high 
altitude. 
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Analysis of correlation networks is a standard tool for drawing biological meaning from 
transcriptomic data (Hume et al., 2010; Mabbott et al., 2010; Summers et al., 2010). As 
we demonstrate here, the same approach may also have substantial utility in classifying 
disease phenotypes. By providing an unbiased allocation of subjects with similar 
symptoms into clusters, it provides a novel and informative method for identifying 
patterns of disease. This method may easily be extended to other syndromes.  
 
Our primary dataset contains repeated measures (1110 questionnaires obtained from 
292 subjects), which may lead to a learning bias in subjects completing the VAS (Van 
Roo et al., 2011). We also used symptom scores from some subjects who were taking 
oral antioxidant supplements or sildenafil for other trials. However these limitations do 
not affect the main outcomes. Repeat analyses focussing only on a single time point, or 
removing subjects on active drug treatments, did not affect the results.  
 
Our study makes use of the largest VAS dataset to date to explore altitude-associated 
symptomatology. As expected, there is a strong correlation between VAS and LLS (Hext 
et al., 2011; Kayser et al., 2010; Van Roo et al., 2011; Wagner et al., 2007). Our work 
extends previous attempts to evaluate VAS scores by demonstrating the utility of VAS in 
creating a normally-distributed, continuous measure of AMS. VAS have a high test-retest 
reliability and inter-rater reliability (Roach, and  Kayser, 2007) and may be more 
sensitive than discrete measures (Grant et al., 1999).  In future research using VAS as an 
endpoint or covariate, improved statistical power may be expected from the use of 
parametric tests that may only be applied to normally-distributed, continuous variables. 
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Furthermore, combining distinct pathophysiological processes into a single summary 
measure carries a risk of introducing excessive noise into studies of the pathogenesis of 
AMS, and of reducing the magnitude of effect signals in therapeutic studies. Focussing 
only on a group of well-correlated symptoms that share common mechanisms will 
further improve the quality of future research into AMS.  
 
To be useful for clinical and physiological studies, a symptom score must accurately 
reflect the severity of a single clinical entity (Bartsch et al., 2004). It is therefore critical 
that all of the symptoms included share an underlying pathogenesis. If not, effective 
treatments will be falsely rejected, and attempts to understand disease processes will 
be obstructed. It is our view that the results presented here should provoke a 
reassessment of consensus diagnostic criteria and severity measures for AMS.  
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Figures 
 
Figure 1. Identification of VAS questionnaires exhibiting similar symptom profiles 
using Biolayout Express 3D.  
Each node (coloured sphere) represents a VAS questionnaire. Nodes are connected by 
weighted lines, which represent correlations between similar symptom profiles. Nodes 
are connected with each other if the Pearson correlation coefficient between them 
exceeds 0.95. The MCL clustering algorithm (inflation = 1.4) sub-divided this network 
into three discrete clusters of VAS questionnaires, each of which shared similar features. 
Figures adjacent to the clusters represent the median VAS scores for each question in 
the VAS questionnaire. The green cluster (cluster 1) contains 407 nodes and 
corresponds to subjects who slept poorly, and were fatigued but had little headache. 
The brown cluster (cluster 2) contains 127 nodes and corresponds to subjects who slept 
poorly and did have headache. The purple cluster (cluster 3) contains 43 nodes and 
corresponds to subjects who had little sleep disturbance but had headache. The 
remaining nodes do not correlate sufficiently with each other to form a significant 
cluster. 
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Figure 2. Frequency distribution of LLS and VAS scores (n=1045).  
(A) Distribution of LLS. A positive LLS, indicating AMS, is a score of 3 or greater in the 
presence of headache; (B) Distribution of Lake Louise Scores following square-root 
transformation; (C) Distribution of total VAS scores (minimum 0mm; maximum 
700mm); (D) Distribution of total VAS scores following square-root transformation of 
data. LLS: Lake Louise Score; VAS: visual analogue scale; AMS: acute mountain sickness. 
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Figure 3. Correlations between different LLS symptoms.  
The correlations between symptoms included in the Lake Louise Score was explored 
across the whole population of responses (n=1045) using Biolayout 3D (minimum 
Pearson correlation cut–off r=0.4).  Headache, fatigue, nausea and dizziness all correlate 
with each other, whereas sleep is an outlier and correlates only with fatigue in this 
model. 
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Table 1 
 Sleep GI upset Dizziness Headache Fatigue 
Sleep x 0.28 0.26 0.31 0.45 
GI upset 0.28 x 0.48 0.42 0.53 
Dizziness 0.26 0.48 x 0.52 0.51 
Headache 0.31 0.42 0.52 x 0.61 
Fatigue 0.45 0.53 0.51 0.61 x 
Average 0.33 0.48 0.50 0.51  0.55 
 
Pearson correlation coefficients between VAS scores for the different symptom 
components of the LLS.  Repeat measures (for GI upset and fatigue) were averaged. 
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Supplementary Figures  
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S1. VAS questionnaire form.  
Questionnaire given to subjects to record VAS scores relating to symptoms experienced 
at altitude on the Apex 2 expedition. The same form was used by participants on the 
Kilimanjaro expedition.  
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S2. Supplementary symptom networks.  
The network graph created in Biolayout 3D Express, which incorporated data from all 
1045 questionnaires and is displayed as Figure 3, was reproduced using differing 
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questionnaire inclusion criteria. These all produced at least two distinct clusters when 
clustered using a MCL inflation value of 1.4. (A) includes questionnaires from Apex 2 
Expedition subjects only (n=869); (B) includes only questionnaires from subjects not 
taking either sildenafil or antioxidant supplementation (n=523); (C) includes 
questionnaires from Kilimanjaro subjects only (n=176); (D) includes only 
questionnaires from subjects at a single time point (day 3 of the Apex 2 expedition, and 
all Kilimanjaro participants, n=269). (E) includes Apex 2 questionnaires, in which the 
sleep score from the following night was used in place of that from the preceding night 
(n=625). 
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S3. Age and sex distribution in symptom network. 
Each node (coloured sphere) represents a VAS questionnaire, connected by weighted 
lines, which represent correlations between similar symptom profiles. Nodes are 
connected with each other if the Pearson correlation coefficient between them exceeds 
0.95. (A) Sex distribution of nodes, with questionnaires completed by males denoted by 
green nodes, those by females by blue, and missing demographic data by grey nodes; 
(B) Age distributions of nodes, with questionnaires completed by under 21 year olds 
represented by orange nodes, 22-25 year olds by pink nodes, and those completed by 
over 26 years old by cyan. Missing data are represented by grey nodes. 
 
 
